[ad_1]
BD (Becton, Dickinson and Company), a leading medical technology company, today announced BD COR CE-IVDD certification™ System in Europe. The high-throughput solution for the diagnosis of infectious diseases sets a new standard in the automation of molecular tests in central laboratories and other major centralized laboratories.
The BD COR™ The system integrates and automates the entire molecular laboratory workflow, from pre-analytical processing to diagnostic test output. The system will be initially available with BD Onclarity™ HPV test for the detection and prolonged genotyping of human papillomavirus (HPV). The system allows the processing of specimens directly from liquid-based cytology vials, the creation of molecular aliquots and assay assays, replacing labor-intensive manual processes and subject-to-work procedures. errors by automated methods.
Over the next few years, the company plans to continue seeking regulatory approvals to sell BD COR.™ System around the world while expanding the content menu to include many other tests for infectious diseases.
The launch of the BD COR system is an important step in our molecular diagnostics roadmap, enabling us to offer pre-analytical automation and high throughput molecular testing to our largest laboratory customers. Over the next few years, we look forward to using this platform to expand our menu and configurations. "
Dave Hickey, President of Diagnostic Systems at BD
The BD COR™ The system, modular and scalable, is designed to meet the multiple needs of laboratories in expanding molecular testing and test volumes. It has an on-board capacity for reagents and samples providing six to eight hours of system processing, eliminating multiple interactions of technicians per shift.
Source:
BD (Becton, Dickinson and Company)
[ad_2]
Source link
